BMW yesterday reported rising profitability in the last quarter despite slowing Chinese sales and the impact of tariffs, offering some rare good news for Germany's beleaguered auto sector.
The premium carmaker also welcomed "positive signals" after China said it would exempt some Nexperia chips from an export ban which had sparked warnings of production stoppages from European manufacturers.
CEO Oliver Zipse said BMW was proving itself "resilient" despite numerous difficulties.
These included "a shifting geopolitical framework with trade impacts such as tariffs, as well as a rapidly evolving market in China," he said.
In the July-September period, BMW posted an operating profit margin in its auto unit, closely watched by investors, of 5.2%, compared to 2.3% in the same period last year.
**media[377907]**
However, tariff costs in the US and the European Union — BMW exports electric vehicles made in China that are subject to EU levies — were weighing on profits, it warned.
BMW has generally sounded more upbeat about riding out Trump's tariff storm than other German automakers as it has a sizeable American footprint, with its biggest plant worldwide in South Carolina.
Its deliveries in the US rose about 25% in the third quarter from a year earlier, while deliveries worldwide were up nearly nine %.
This is far better than domestic rivals Volkswagen and Mercedes-Benz. VW, Europe's biggest carmaker, last week warned that the US tariffs were set to cost it €5bn a year.
But BMW, whose brands also include Mini and Rolls-Royce, is not immune to the current turmoil in the European auto sector.
It cut its outlook for 2025 in October due to tariff costs and worsening prospects in China, where German firms are being challenged by local rivals for electric sales.
Sales in China were down slightly in the July to September period, BMW said.
BMW also said that research and development spending had fallen significantly in 2025 compared to last year, when it splashed huge sums on building up a new range of EVs that the carmaker hopes can help it compete in China.
Zipse welcomed signs of easing tensions after China's weekend announcement on softening the export ban on Nexperia semiconductors, which it imposed due to a fight with the Netherlands over control of the chipmaker.
The situation at BMW with regard to supply of chips, crucial to cars' onboard electronics, was currently "going well", Zipse said, but warned that it was still "volatile".
"We continue to assess the situation — we do this several times a day," he told journalists on a call.
The group's net profit in the third quarter came in at €1.7bn ($1.9bn), in line with forecasts.
This was sharply up from €476mn in the same period in 2024, when results were heavily impacted by a massive vehicle recall. Revenues were flat at around €32bn.
Novo Nordisk
Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as sales growth slows, but investors cheered a better-than-expected Medicare pricing deal that helped lift the shares after an initial slide.
Novo is going through a tumultuous period marked by a share price plunge and slowing sales growth, which have prompted a change of CEO and a board shake-up. It's also in a bidding war with US rival Pfizer for biotech Metsera.
CEO Mike Doustdar, who took the helm in August and is driving a turnaround plan, is trying to claw back lost ground in a fiercely competitive obesity drug market against US rival Eli Lilly, which posted far stronger results last week.
Doustdar said on a media call that Novo was working to expand its direct-to-consumer sales in the US and was confident it would beat Pfizer in acquiring obesity drug developer Metsera.
Novo said its guidance cut — the fourth this year — was due to a weaker growth outlook for the firm's blockbuster treatments Wegovy and Ozempic for weight loss and diabetes.
But Novo also said it had agreed pricing for semaglutide — the active ingredient in the two drugs — under the US Medicare scheme, addressing a major uncertainty for investors worried that the Trump administration would take a tough line in talks.
Novo did not disclose the agreed price, but said that if applied this year it would have had a "low-single-digit negative impact on sales".
JP Morgan analysts estimated this could equate to around a 6bn Danish crown ($937mn) hit to sales, adding that was "better than feared" and could offset the negative news from the guidance cut.
"The shares could ultimately be in positive territory today," they wrote in a note.
Fuelled by the rapid take-up of Wegovy, the first in a new class of drugs called GLP-1 receptor agonists, Novo became Europe's most valuable firm last year. But sales growth has slowed sharply amid competition from Eli Lilly and compounded copycat drugs made from the same ingredients as branded drugs.
Novo's market value peaked in June 2024 at around $650bn, but has since fallen by about 70%, close to its value around Wegovy's launch in 2021.
Novo now expects full-year operating profit — measured in local currencies — to grow between 4% and 7%, down from 4%-10% previously. It trimmed its outlook for 2025 sales growth to between 8% and 11%, compared with its previous 8%-14% range.
The company expects sales growth to slow further in the fourth quarter, after growing at the slowest pace since early 2022 in the third quarter at 11%, just shy of 11.4% estimates.
Mikael Bak, head of the Danish Shareholders' Association which has 17,000 members — a majority of them invested in Novo — said the third-quarter update was not a surprise, but it was "nevertheless a disappointment".
"We support the transformation process now underway and view this as a moment for patience, focus, and disciplined execution," he added.
UBS analysts said investors would be disappointed by the magnitude of the guidance cut and the growth outlook.
Novo warned that unlawful mass compounding — copycat drugs custom-made from the same ingredients as branded drugs — continued in the third quarter.
Sales of Wegovy rose 18% year-on-year in the period to 20.4bn crowns, versus analysts' forecasts of 20.9bn. Weekly prescriptions in the US for Wegovy had fallen by 10,000 over the last three months to around 270,000, the company said.
Operating profit fell 30% to 23.7bn crowns, below the expected 24.6bn crowns.
Barry Callebaut
Swiss chocolate group Barry Callebaut reported a drop in annual net profit on Wednesday as high cocoa prices and falling consumption took a bite out of its earnings.
Barry Callebaut, whose financial year runs through the end of August, said its profit after tax fell 1.3 % to 188.4mn Swiss francs ($233mn) in the 2024-2025 period.
Revenue rose 42.4% to 14.8bn francs as the supplier of cocoa and chocolate products passes fluctuations in raw material prices on to clients.
In terms of volume, however, sales fell 6.8% to 2.1mn tonnes.
Barry Callebaut supplies cocoa and chocolate products to major food groups such as Oreo cookie producer Mondelez, KitKat maker Nestle and Magnum ice cream owner Unilever.
"The past fiscal year was marked by exceptional and unprecedented volatility in the cocoa and chocolate markets, impacting both Barry Callebaut and our customers," chief executive Peter Feld said in an earnings statement.
Cocoa prices have soared for two consecutive years, reaching a historic high in December 2024 at $12,931 per tonne in New York and 10,100 pounds per tonne in London.
Bouygues
French conglomerate Bouygues reported a stronger than expected operating profit for the first nine months of the year on Wednesday, helped by resilient construction activities even as political turmoil in France weighed on its media arm.
Current operating profit from activities was €1.81bn ($2.11bn) between January and September, slightly above the €1.77bn euros expected by analysts polled by the company. Group sales reached €41.86bn euros, broadly in line with the consensus.
Family-owned Bouygues, whose activities span from construction and energy services to media and telecommunications, is leading a joint effort to consolidate France's telecoms market by carving up a large portion of Altice France, which owns the country's second-largest operator SFR. The €17bn offer, launched together with Orange and Iliad, was rejected by Altice France in October. Still, the trio has stood by the bid and stated its intention to pursue talks with Altice shareholders.
"There was no particular dialogue before, and there is no particular dialogue after," Deputy CEO Pascal Grangé said in a call with reporters. "The offer we made was clearly not acceptable to Altice. That is where we stand today."
The construction business benefitted from a strong order book and offset weaker advertising that weighed on the media unit. The company has secured a major civil works role at Britain's Sizewell C nuclear project, with orders worth about €3bn to be booked from late 2025.
Marks and Spencer
British clothes-to-food retailer Marks and Spencer on Wednesday said a cyberattack that affected its online service sent profits sliding in the group's first half.
Net profit plunged 98% to £6.2mn ($8.1mn) in the six months to late September, compared with profit after tax of £282.1mn one year earlier, M&S said in a statement.
The company halted online sales for about six weeks after hackers targeted the business around Easter, stealing some customer data.
"The first half of this year was an extraordinary moment in time for M&S," its chief executive Stuart Machin said in the earnings release.
"However, the underlying strength of our business and robust financial foundations gave us the resilience to face into the challenge and deal with it."
The group forecast that its second-half profit would be "at least in line with last year, as the residual effects of the incident continue to reduce in the coming months".
M&S flagged in May that the cyberattack would cost the group around £300mn.
On Wednesday, it booked a charge of £101.6mn on dealing with the incident such as fixing systems.
It expects a further hit totalling about £34mn in the group's second half, while M&S has managed to recover £100mn via an insurance payout.
Emphasising its robust underlying performance, sales grew 22% in the reporting period to almost £8bn.
The company's share price dipped 0.1 % in early London trading.